Clinical Trial Update: Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on the immunogenicity and safety of a bivalent meningococcal A and C tetanus toxoid conjugate vaccine in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine

Snippet

Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Conditions: Vaccine | Phase 3 | Status: COMPLETED